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Abstract
Purpose Metastatic melanoma patients have a poor
prognosis. No chemotherapy regimen has improved overall
survival. More effective treatments are needed. Docetaxel
has clinical activity in melanoma and may be more active
when combined with vinorelbine. Granulocyte–macro-
phage colony-stimulating factor (GM-CSF) has shown
activity as an adjuvant melanoma therapy. We carried out a
phase II study of these agents in patients with stage IV
melanoma.
Methods Patients had documented stage IV melanoma
and may have had prior immuno or chemotherapy. Previ-
ously treated brain metastases were allowed. Docetaxel
(40 mg/m
2 IV) and vinorelbine (30 mg/m
2 IV) were
administered every 14 days, followed by GM-CSF
(250 mg/m2 SC on days 2 to 12). The primary endpoint of
the study was 1-year overall survival (OS). Secondary
objectives were median overall survival, response rate (per
RECIST criteria), and the toxicity proﬁles.
Results Fifty-two patients were enrolled; 80% had stage
M1c disease. Brain metastases were present in 21%. Fifty-
two percent of patients had received prior chemotherapy,
including 35% who received prior biochemotherapy.
Toxicity was manageable. Grade III/IV toxicities included
neutropenia (31%), anemia (14%), febrile neutropenia
(11.5%), and thrombocytopenia (9%). DVS chemotherapy
demonstrated clinical activity, with a partial response in
15%, and disease stabilization in 37%. Six-month PFS was
37%. Median OS was 11.4 months and 1-year OS rate was
48.1%.
Conclusions The DVS regimen was active in patients
with advanced, previously treated melanoma, with man-
ageable toxicity. The favorable 1-year overall survival and
median survival rates suggest that further evaluation of the
DVS regimen is warranted.
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Introduction
There are an estimated 68,130 new cases of malignant
melanoma and 8,700 deaths annually in the United States
[1]. Although curable in its early stages, melanoma is the
most common fatal form of skin cancer. Patients having
metastatic disease have a poor prognosis, with median
survival time of less than 9 months and a less than 5%
probability of survival beyond 5 years of diagnosis [2].
Currently, dacarbazine and interleukin-2 (IL-2) are the only
US Food and Drug Administration–approved agents for the
treatment of metastatic melanoma. Response rates after
treatment with dacarbazine have been approximately 12%,
with no increased survival [3]. Immunotherapy with IL-2
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DOI 10.1007/s00280-011-1703-zproduces responses in approximately 13% of stage IV
patients, of which 4% are complete responses, with a
subset enjoying durable disease-free survival [4, 5].
Although response rates are signiﬁcantly increased for
combinations of chemotherapy such as cisplatin, vinblas-
tine, and dacarbazine (CVD regimen) with IL-2 and
interferon-alpha (biochemotherapy), phase III trials have
failed to show a signiﬁcant overall survival beneﬁt [6–8].
More recently, ipilimumab has been reported to improve
survival by approximately 4 months compared to a gp100
melanoma vaccine [9]. However, both biochemotherapy
and immunotherapy are associated with increased consti-
tutional, hemodynamic, and myelosuppressive toxicity that
can adversely affect quality of life. While recent approaches
targeting molecular abnormalities, such as PLX4032, a
tyrosine kinase inhibitor of BRAF, have generated enthu-
siasm, response duration appears to be limited [10, 11].
As current treatment regimens offer limited beneﬁts to
patients, more effective and less toxic treatments are nee-
ded. In preclinical studies, docetaxel (Taxotere) and vino-
relbine (Navelbine) showed signiﬁcant independent in vitro
activity against melanoma specimens. The taxane paclit-
axel and the vinca alkaloid derivative vinorelbine have
been shown to act synergistically in vitro against mela-
noma cell lines, with both agents active in the nanomolar
range at clinically achievable concentrations [12, 13].
Using an ex vivo adenosine triphosphate (ATP)– based
chemosensitivity assay, Neale et al. demonstrated that 43%
of vinorelbine-treated and 33% of paclitaxel-treated cuta-
neous melanomas showed sensitivity in the assay [13].
Furthermore, metronomic docetaxel has also been associ-
ated with anti-angiogenesis activity [14].
The safety and clinical activity of the docetaxel and
vinorelbinecombinationhave beendemonstrated inpatients
with metastatic non-small cell lung cancer and metastatic
breast cancer [15–17]. Retsas et al. evaluated the toxicity
and activity of two sequences of paclitaxel combined with
vinorelbine in disseminated malignant melanoma in 15
patients [18]. There were no problems with anaphylactic
episodes, signiﬁcant neutropenia, or emesis. The main tox-
icity noted was alopecia. Three major responses were seen,
along with clinically meaningful tumor regressions that did
not qualify as major responses in two additional patients. In
metastatic melanoma patients, vinorelbine as a single agent
has had a favorable toxicity proﬁle, but showed limited
clinicalefﬁcacyintwotrialswith13and21patients[19,20].
A somewhat better outcome was seen for vinorelbine in
combinationwithtamoxifen,wherea20%responseratewas
observedin30patients[21].Wechosetocombinedocetaxel
(40 mg/m
2 IV) with vinorelbine (30 mg/m
2 IV) adminis-
teredevery2 weeksinametronomicfashion.Wepostulated
that this schedule would possess both antitumor and anti-
angiogenesis activity.
Granulocyte–macrophage colony-stimulating factor
(GM-CSF, sargramostim [Leukine]) may have beneﬁt as an
adjuvant therapy in stage III and resected stage IV mela-
noma. GM-CSF is integral to the functioning of the
immune system, and results in activation of macrophages
and dendritic cells, which may serve as antigen-presenting
cells [22]. In vitro, GM-CSF stimulates peripheral blood
monocytes to become cytotoxic to human melanoma cells
[23, 24]. Administration of GM-CSF to patients results in
an increase in the functional capacity of monocytes, as
reﬂected by increased cytotoxicity [25, 26]. Additionally,
GM-CSF, through its action on tumor-inﬁltrating macro-
phages, causes the production of angiostatin, an angio-
genesis inhibitor [27, 28]. In two separate melanoma
models, GM-CSF was found to be the most effective of the
cytokines studied for induction of long-term protective
immunity [29, 30].
GM-CSF was studied as an adjuvant to surgery in
patients with metastatic melanoma in a phase II study by
Spitler and colleagues. The survival rate at 1 year for
patients receiving GM-CSF was almost double (89% vs.
45%) that of historically matched controls [31]. GM-CSF
was recently evaluated in a phase III cooperative group
study as an adjuvant treatment for patients with completely
resected stage III–IV melanoma, which demonstrated a
signiﬁcant improvement in disease-free survival, but not in
overall survival [32]. We therefore evaluated the activity of
the DVS combination (docetaxel, vinorelbine, and GM-
CSF [sargramostim]) for the treatment of patients with
stage IV melanoma in order to offer a combination of
antitumor and anti-angiogenesis effects in tandem with
immunostimulation.
Methods
Patients
Adult patients with a diagnosis of biopsy-proven stage IV
metastatic melanoma, who had received no more than two
prior chemotherapy or biotherapy regimens for metastatic
disease, were eligible. Patients with brain metastases were
eligible, if metastases were controlled with radiotherapy
and asymptomatic. Other eligibility criteria included East-
ern Cooperative Oncology Group (ECOG) performance
status of 2 or less, absolute neutrophil count (ANC) C
1,500/mm
3, platelet count[100,000/mm
3, hemoglobin[
10 g/dl, BUN and serum creatinine\0.5 9 upper limit of
laboratory normal (ULN), total and direct biliru-
bin\1.5 9 ULN, SGOT and SGPT\3 9 ULN, alkaline
phosphatase\3 9 ULN, and a life expectancy of at least
12 weeks. Patients were excluded if they had received
cancer treatments including radiation within 4 weeks,
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known HIV/AIDS, or an acute infection being treated with
IV antibiotics. Institutional review board approval was
obtained for the study protocol, and all patients provided
written informed consent prior to entering study.
Study design
The DVS regimen consisted of docetaxel 40 mg/m
2 IV
over 1 h, vinorelbine 30 mg/m
2 IV over 6 to 10 min on day
1, every 14 days, and GM-CSF, 250 mg/m
2 SC on days 2
to 12. Patients received a cycle of this regimen every
2 weeks.
Clinical assessments
Prior to treatment, patients underwent complete history and
physical examinations, baseline computed tomographic
(CT) scans of chest, abdomen, pelvis, MRI of brain or CT
head with contrast, and laboratory tests including complete
blood count and differential, metabolic panel and liver
function panel. Every 2 weeks patients had history and
physical, toxicity assessment, and repeated laboratory
testing done.
Tumor response was assessed with Response Evalua-
tion Criteria in Solid Tumors (RECIST) every two cycles
(every 8 weeks) [33]. All sites of disease at baseline were
documented. CT scans of the chest, abdomen, and pelvis
were performed every 8 weeks. Complete response (CR)
was deﬁned as the disappearance of all lesions; partial
response (PR) was deﬁned as at least a 30% decrease in
sum of longest diameter from baseline with no new
lesions or progression of nontarget lesions; and progres-
sive disease (PD) was deﬁned as a 20% increase in sum
of longest diameter from the smallest measurement since
the start of treatment, unequivocal progression in non-
target lesions, or the appearance of any new lesion.
Patients not progressing for a minimum of 8 weeks as
conﬁrmed by CT imaging were considered to have stable
disease (SD).
Toxicity was graded according to National Cancer
Institute Common Terminology Criteria of Adverse
Events, version 3.0. Safety was assessed through adverse
event monitoring, physical examinations, vital signs, and
clinical laboratory tests, including full hematology and
chemistry panels done before each dosing. Chemotherapy
doses were reduced by 20 percent in cases of persistent
hematologic toxic effects or grade 3 or 4 non-hematologic
toxic effects. Patients who discontinued study treatment
were followed every 3 months, or until death, to collect
data on overall survival.
Statistical analysis
The primary outcome was 1-year overall survival, with
secondary endpoints of 1-year overall survival, median
overall survival, tumor response rate, and safety. Overall
survival and progression-free survival endpoints were
assessed using the Kaplan–Meier product limit method. A
95% conﬁdence interval for the median survival time and
median progression-free survival time was calculated using
the Brookmeer and Crowley method [34].
A 2008 meta-analysis by Korn et al. examined phase II
cooperative group trials in metastatic melanoma to
determine overall survival benchmarks for single-arm
phase II trials [35]. The study included predicted 1-year
overall survival rates for patients determined from a
logistic regression model based on gender, performance
status, presence of visceral disease, and whether the trial
included brain metastases patients. For each patient on the
trial, the authors recommend obtaining his or her pre-
dicted 1-year overall survival rate from provided tables,
and determining the average of the predicted values for
the patient cohort (i.e., the historical control rate). After
the trial is complete, the proportion of patients alive at
1 year is obtained and compared to the calculated his-
torical control rate. They suggested that the treatment may
be worthy of further study if a comparison of the two
rates gives a P-value\0.10.
Results
Patients
Fifty-two patients were enrolled in the trial and began
treatment. Patient characteristics are summarized in
Table 1. Patients with distant metastases are subclassiﬁed
according to the site(s) of disease involvement and the
serum lactic dehydrogenase (LDH) level [36]. Patients with
M1a disease only have distant skin, subcutaneous, or
lymph node metastases with normal LDH levels and have
the best prognosis. M1b disease indicates lung metastases
with normal LDH. Patients with M1c disease have other
visceral metastases, or metastases with an elevated LDH,
and have the worst prognosis. Approximately eighty per-
cent of the patients in this trial had M1c disease. Lung, soft
tissue, and lymph nodes were the most common sites of
metastatic disease; 21.2% of patients also had brain
metastases. Two-thirds of patients had received prior bio-
logical or chemotherapy; 51.9% had chemotherapy and
34.6% had prior IL-2 or interferon treatment. Fifty percent
of patients had prior treatment after diagnosis with stage IV
melanoma.
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There were no complete responses, and 8 partial responses,
for an objective response rate of 15.4%. Table 2 shows best
overall response per RECIST criteria. All patients were
included in the response rate calculation, including nine
patients with no post-baseline CT scan who were counted
as non-responders (of the nine, only one died prior to CT
scan). Clinical beneﬁt rate (CR ? PR ? SD) was 52%.
One patient is still currently on study.
Toxicity
Toxicity observations were based on all treated patients.
All patients reported at least one treatment-related adverse
event. The majority of observed adverse events were mild
or moderate (grades 1 or 2) in severity. Most common
grade 1 or 2 events were alopecia, anemia, and fatigue
(Table 3). The most common grade 3 or 4 toxicity was
neutropenia, which occurred in 16 patients, followed by
anemia in 8 patients. Only one patient had to be removed
from the study secondary to prolonged neutropenia; four
other patients requested to be taken off study secondary to
intolerance of side effects. There were no treatment-related
deaths.
Progression-free survival
Figure 1 shows the Kaplan–Meier plot of progression-free
survival. Median progression-free survival was calculated
at 134 days (4.8 months), with a 95% conﬁdence interval
of 91 to 214 days. Patients who were still alive and had not
yet progressed were censored. For these patients, date of
their last clinical assessment by investigator without pro-
gression was entered as date of censoring. One patient who
died prior to ﬁrst CT scan assessment was counted as
having progressed. Four patients had central nervous sys-
tem (CNS) progression. One had intracerebral hemorrhage
Table 1 Patient demographics and clinical characteristics
No. of
patients
%o f
patients
Age
Median 62.0
Range 24–82
Sex
Male 37 71.1
Female 15 28.9
Disease sites
Lung 34 65.4
Node 27 51.9
Liver 14 26.9
Soft tissue 13 63.5
Pelvis 8 15.4
Bone 8 15.4
Brain 11 21.2
Performance status
0 48 92.3
1 4 7.7
Grade of metastatic disease
M1a 2 3.8
M1b 8 15.4
M1c 42 80.8
Prior therapy
Prior cancer surgery 52 100
No prior biologics or chemotherapy 17 32.7
Biologics (interleukin-2, interferon) 18 34.6
Chemotherapy 27 51.9
Vaccine 5 9.6
Radiation therapy 22 42.3
Table 2 Best overall response
No. of
patients
%o f
patients
Complete response 0 0
Partial response 8 15.4
Stable disease 19 36.5
Progressive disease 16 30.7
Unknown/no post-baseline assessment
(counted as non-responder)
9 17.3
Overall response 15.4%
Table 3 Adverse events related to DVS regimen occurring in 10% or
more of participants
Adverse event Grade 1, 2 n (%) Grade 3, 4 n (%)
Anemia 34 (65.4) 8 (15.4)
Neutropenia 3 (5.8%) 16 (30.8)
Febrile neutropenia – 6 (11.5)
Thrombocytopenia 6 (11.5) 3 (5.8)
Fatigue 21 (40.4%) 4 (7.7)
Sensory neuropathy 16 (30.8) 0
Nausea/vomiting 16 (30.8) 1 (1.9)
Diarrhea 12 (23.1) 0
Anorexia 13 (25) 1 (1.9)
Bone pain 9 (17.3) 0
Injection site reaction 12 (23.1) 1 (1.9)
Edema 12 (23.1) 0
Taste changes 8 (15.4) –
Drug fever 6 (11.5) 0
Chills 9 (17.3) 0
Alopecia 50 (96.2) –
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tases as well and was taken off study; the third complained
of fatigue and asked to be taken off study. However, the
fourth patient with new brain metastases, who had no
progression of systemic metastases, was continued on the
trial, as this regimen is not considered active against CNS
metastases. 6-month progression-free survival rate was
37%.
Overall survival
Median overall survival was calculated at 320 days
(11.4 months), with 95% conﬁdence interval of 190 to
390 days. Figure 2 shows the Kaplan–Meier product limit
estimation plot of overall survival. Twenty-ﬁve of 52
patients were alive after 1 year, resulting in a 1-year
overall survival rate of 48.1%. Based on the method for
determining predicted survival rates recommended by
Korn et al., a historical 1-year overall survival rate of
24.3% was obtained for our patient cohort. A comparison
of the two survival rates gives a P-value of 0.012, indi-
cating that this regimen merits further study. The differ-
ence between the historical and observed 1-year survival
rate was 23.8%, with a 95% conﬁdence interval of 4–41%.
At the end of the observation period in October 2010,
eleven patients (21.2%) were still alive and were censored
on the Kaplan–Meier curve (shown as tick marks). Nine
patients were alive 2 years after starting treatment, and two
patients were alive after 6 years.
Discussion
Anemia and neutropenia were the most frequent grade 3 or
4 adverse events related to the DVS regimen. This was
expected, given the known toxicities of docetaxel. This was
also not surprising considering that two-thirds of patients
had received prior treatment with biological or chemo-
therapy agents, with many having recently completed other
melanoma regimens, which may have contributed to the
myelosuppresion seen in some of the patients. One patient
had to be taken off study for prolonged neutropenia;
however, there were no other unexpected adverse events or
treatment-related deaths. The toxicity of the DVS regimen
thus appears superior compared to CVD-biochemotherapy
or high-dose IL-2.
For the trial reported here, patients treated with the DVS
regimen had a median progression-free survival of
4.8 months. The objective response rate of 15.4% is similar
to that seen with other chemotherapy regimens used to treat
melanoma. However, therapy with DVS led to median
overall survival of 11.4 months, and a 1-year overall sur-
vival of 48.1%. This rate was approximately twofold
higher than the 24.3% predicted survival rates calculated
according to the methods described by Korn et al. and was
statistically signiﬁcant (P\0.012), indicating that this
regimen merits further study. While this regimen did not
result in a high response rate, it led to prolonged survival
for both previously treated and untreated patients with
advanced melanoma. This outcome may be related to
immune modulation by GM-CSF in combination with
antiangiogenic and antitumor effects mediated by metro-
nomic docetaxel (14, 31–32). The 1-year survival seen for
this patient cohort compares favorably with dacarbazine,
temozolomide, IL-2, and CVD-biochemotherapy treat-
ments. While the DVS regimen appears to be active in
prolonging survival for both previously treated and
untreated patients with advanced melanoma, subset anal-
ysis was not performed due to the small sample size of
treatment naı ¨ve cases (33%).
It should be noted as a caveat that the Korn data were
derived from multi-institutional trials performed over many
decades, rather than a short-term one-institution study.
There are potential selection biases implicit in our trial and
current prognostic variables that are not factored into the
Korn model, which may have affected patient survival.
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Fig. 1 Kaplan–Meier plot of progression-free survival (n = 52, 7
cases censored; median PFS = 134 days)
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Fig. 2 Kaplan–Meier plot of median overall survival (n = 52, 11
cases censored; median OS = 320 days)
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123Nevertheless, the Korn analysis provides a useful bench-
mark for consideration. Based on our observed efﬁcacy and
toxicity proﬁles, the docetaxel, vinorelbine, and GM-CSF
regimen is of interest for further study in randomized phase
III trial.
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